Renal replacement therapy in autosomal dominant polycystic kidney disease.
Autosomal dominant polycystic kidney disease (ADPKD) accounted for 4.6% of our end-stage renal disease (ESRD) population. Initial ESRD therapy consisted of hemodialysis in 78% and continuous ambulatory peritoneal dialysis in 22% with significant intertherapy transfers. Half of these patients underwent one or more renal transplantations. Infections, primarily related to ADPKD or ESRD therapy, were the leading cause of morbidity in these patients. 3% of total time on ESRD therapy was spent in hospital, half of it due to problems related to ADPKD and ESRD therapy. Overall mortality and morbidity (as measured by hospitalization rates) in ADPKD patients were similar to those in a non diabetic ESRD population.
Singh
S
S
University of Cincinnati Medical Center, Dialysis Clinic Inc., Ohio.
Hariharan
S
S
D000328:Adult; D005260:Female; D005799:Genes, Dominant / Q000235:genetics*; D006801:Humans; D007674:Kidney Diseases / Q000235:genetics / Q000401:mortality / Q000601:surgery; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D007690:Polycystic Kidney Diseases / Q000235:genetics / Q000401:mortality / Q000601:surgery*